Tianjin Development (00882) announced that its indirectly non-wholly owned subsidiary Tianjin Lisheng Pharmaceutical achieved a total operating income of 1.024 billion yuan as of September 30, 2024...
According to the Zhitong Finance APP, Tianjin Development (00882) announced that its indirectly non-wholly owned subsidiary Tianjin Lisheng Pharmaceutical achieved a total operating income of 1.024 billion yuan as of September 30, 2024, with a 12.3% year-on-year increase; a net income attributable to the owners of the parent company of 0.169 billion yuan, a 50.6% year-on-year decrease; and a basic earnings per share of 0.66 yuan.
